<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages>en</availableLanguages>
  <rcn>269446</rcn>
  <id>101207615</id>
  <acronym>NanoNAD</acronym>
  <teaser>Metabolic decline may be a critical, and treatable, pathogenic component of glaucoma. Glaucoma is one of the most prevalent neurodegenerations worldwide, affecting 80 million patients worldwide. There are no neuroprotective therapies.We have discovered metabolic and...</teaser>
  <objective>Metabolic decline may be a critical, and treatable, pathogenic component of glaucoma. Glaucoma is one of the most prevalent neurodegenerations worldwide, affecting 80 million patients worldwide. There are no neuroprotective therapies.
We have discovered metabolic and mitochondrial dysfunction in the retina and optic nerve which occur prior to neurodegeneration in glaucoma. One of these early changes is a decline in the important metabolite nicotinamide adenine dinucleotide (NAD), which critically regulates neuronal survival in glaucoma. Preventing NAD decline pharmacologically or through targeted gene therapies robustly prevents neurodegeneration. We are now actively generating novel NAD-generating compounds based on our initial studies. Neuronal NAD production is an ideal target for neuroprotective drug discovery for neuroprotection in glaucoma and other axon degenerations.
The goal of this research project is to develop clinically translatable nano-enabled neuroprotective strategies for glaucoma. I will focus on these novel strategies involving compounds that increase NAD metabolism developed by the Williams lab and formulated in nanocarriers by the Sotiriou lab. These will be translated into practical, effective agents that provide long-term effects in the retina. The current challenges we face are: (1) ocular delivery without toxicity, (2) high pay-load delivery, (3) delivery with sustained release. To overcome these, the Williams and Sotiriou labs will collaborate, where I will: (1) rationally design biocompatible nanocarriers by flame spray pyrolysis, (2) load these nanocarriers with novel NAD-generating drugs, (3) evaluate their NAD-generating capacity in vivo and the resulting neuroprotective effects. With this project, I will combine the expertise from the two laboratories to facilitate the integration of visual neuroscience, pharmacology, and nanoscale drug delivery systems to develop clinically translatable therapies for ophthalmic disease.</objective>
  <title>Nanoparticle-mediated ocular delivery of novel NAD-boosting small molecules for ophthalmic disease.</title>
  <totalCost>0</totalCost>
  <ecMaxContribution>252180</ecMaxContribution>
  <startDate>2025-04-01</startDate>
  <endDate>2027-03-31</endDate>
  <ecSignatureDate>2025-03-12</ecSignatureDate>
  <duration>24</duration>
  <status>SIGNED</status>
  <keywords>Glaucoma, retinal ganglion cells, nicotinamide adenine dinucleotide (NAD), mitochondrial metabolism, nanoparticle, drug delivery</keywords>
  <identifiers>
    <grantDoi>10.3030/101207615</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2025-06-17 07:47:40</sourceUpdateDate>
  <contentCreationDate>2025-03-18 17:16:51</contentCreationDate>
  <contentUpdateDate>2025-06-30 16:26:28</contentUpdateDate>
  <lastUpdateDate>2025-10-27 16:44:48</lastUpdateDate>
  <terminationDate>2025-06-30 00:00:00</terminationDate>
  <relations>
    <associations>
      <call source="corda" type="relatedMasterCall">
        <rcn>56116</rcn>
        <title>HORIZON-MSCA-2024-PF-01</title>
        <identifier>HORIZON-MSCA-2024-PF-01</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>56116</rcn>
        <title>HORIZON-MSCA-2024-PF-01</title>
        <identifier>HORIZON-MSCA-2024-PF-01</identifier>
      </call>
      <organization netEcContribution="252180" totalCost="0" source="corda" order="1" ecContribution="252180" terminated="false" sme="false" type="coordinator">
        <availableLanguages>en</availableLanguages>
        <rcn>1906240</rcn>
        <id>999978530</id>
        <vatNumber>SE202100297301</vatNumber>
        <legalName>KAROLINSKA INSTITUTET</legalName>
        <shortName>KAROLINSKA INSTITUTE</shortName>
        <address>
          <street>NOBELS VAG 5</street>
          <city>STOCKHOLM</city>
          <postalCode>171 77</postalCode>
          <country>SE</country>
          <postBox>N/A</postBox>
          <url>http://www.ki.se</url>
          <geolocation>59.3481714,18.0250493</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/HES</code>
              <title>Higher or Secondary Education Establishments</title>
              <displayCode>/Higher or Secondary Education Establishments</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Stockholms län</name>
              <rcn>473436224</rcn>
              <nutsCode>SE110</nutsCode>
              <parents>
                <region>
                  <name>Stockholm</name>
                  <rcn>473436264</rcn>
                  <nutsCode>SE11</nutsCode>
                  <parents>
                    <region>
                      <name>Östra Sverige</name>
                      <rcn>473438760</rcn>
                      <nutsCode>SE1</nutsCode>
                      <parents>
                        <region>
                          <name>Sweden</name>
                          <rcn>473598504</rcn>
                          <nutsCode>SE</nutsCode>
                          <euCode>SE</euCode>
                          <isoCode>SE</isoCode>
                        </region>
                      </parents>
                    </region>
                  </parents>
                </region>
              </parents>
            </region>
            <region type="relatedRegion">
              <name>Sweden</name>
              <rcn>473598504</rcn>
              <nutsCode>SE</nutsCode>
              <euCode>SE</euCode>
              <isoCode>SE</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme type="relatedLegalBasis" source="corda" uniqueProgrammePart="true">
        <availableLanguages>en</availableLanguages>
        <rcn>705729</rcn>
        <id>HORIZON.1.2</id>
        <code>HORIZON.1.2</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.1.2</pga>
        <title>Marie Skłodowska-Curie Actions (MSCA)</title>
        <parent>
          <programme>
            <rcn>705726</rcn>
            <code>HORIZON.1</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode>/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme type="relatedTopic" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>708088</rcn>
        <id>HORIZON_HORIZON-MSCA-2024-PF-01-01</id>
        <code>HORIZON-MSCA-2024-PF-01-01</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>MSCA Postdoctoral Fellowships 2024</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode>/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1366622</rcn>
        <id>101207615_PSHORIZON</id>
        <title>Periodic Reporting for period 1 - NanoNAD (Nanoparticle-mediated ocular delivery of novel NAD-boosting small molecules for ophthalmic disease.)</title>
        <description>periodic</description>
        <teaser>Glaucoma is a common neurodegenerative disease affecting ~80 million people worldwide and is the leading cause of irreversible blindness. It is characterized by the progressive degeneration and loss of retinal ganglion cells (RGCs), the output neurons of the retina. Age...</teaser>
        <sourceUpdateDate>2025-10-20 17:42:54</sourceUpdateDate>
        <contentUpdateDate>2025-10-27 16:44:44</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/pubsum</code>
              <title>Report Summary</title>
              <description>Result: Publishable summary (FP7 SESAM) and Summary for publication (H2020 SyGMa)</description>
              <displayCode>/Report Summary</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode>/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/23/49/327</code>
        <title>neurobiology</title>
        <displayCode>/natural sciences/biological sciences/neurobiology</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/39/213/703</code>
        <title>glaucoma</title>
        <displayCode>/medical and health sciences/clinical medicine/ophthalmology/glaucoma</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/35/159</code>
        <title>pharmacology and pharmacy</title>
        <displayCode>/medical and health sciences/basic medicine/pharmacology and pharmacy</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="40">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode>/Digital agenda</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="40">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode>/Clean air</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="40">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode>/Artificial intelligence</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="40">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode>/Climate action</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode>/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages>en</availableLanguages>
        <code>/HORIZON-TMA-MSCA-PF-EF</code>
        <title>HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships</title>
        <description>HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships</description>
        <displayCode>/HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode>/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>